4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease

Lafora disease (LD) is a rare adolescent-onset progressive myoclonic epilepsy caused by loss-of-function mutations either in the EPM2A gene encoding laforin or in the EPM2B gene encoding malin. Mouse models with deletion in the Epm2a or the Epm2b gene show intracellular aggregates of polyglucosans (Lafora bodies) and neurological complications that resemble those observed in patients with LD. In the absence of laforin or malin expression, mice also show different degrees of hyperexcitability, as reflected by an enhanced response to the convulsant drug pentylenetetrazol (PTZ). Malin knockout mice treated with 4-phenylbutyric acid (4-PBA) and metformin showed decreased amounts of Lafora bodies and polyubiquitin protein aggregates in the brain, diminished neurodegeneration, and amelioration of some neurological conditions. In this study, we analyzed the action of 4-PBA and metformin treatments on response to PTZ in a malin knockout model of LD. Both treatments decreased seizure susceptibility, bringing about a reduction in both seizure number and length, and eliminated the mortality induced by PTZ. These results show a neuroprotective role of 4-PBA and metformin and extend the beneficial effects reported in the malin knockout model of LD Video abstract: http://links.lww.com/WNR/A411.

[1]  J. Serratosa,et al.  Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease , 2016, Molecular Neurobiology.

[2]  J. Serratosa,et al.  Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole , 2014, Front. Neurosci..

[3]  F. Pallardó,et al.  Increased Oxidative Stress and Impaired Antioxidant Response in Lafora Disease , 2014, Molecular Neurobiology.

[4]  J. Serratosa,et al.  Laforin and Malin Deletions in Mice Produce Similar Neurologic Impairments , 2012, Journal of neuropathology and experimental neurology.

[5]  P. Bovolenta,et al.  Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. , 2012, Human molecular genetics.

[6]  K. Yamakawa,et al.  Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease. , 2012, Human molecular genetics.

[7]  J. Delgado-García,et al.  Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease , 2011, EMBO molecular medicine.

[8]  A. Depaoli-Roach,et al.  Genetic Depletion of the Malin E3 Ubiquitin Ligase in Mice Leads to Lafora Bodies and the Accumulation of Insoluble Laforin* , 2010, The Journal of Biological Chemistry.

[9]  W. Ladiges,et al.  Phenylbutyric Acid Rescues Endoplasmic Reticulum Stress-Induced Suppression of APP Proteolysis and Prevents Apoptosis in Neuronal Cells , 2010, PloS one.

[10]  A. Depaoli-Roach,et al.  Abnormal Metabolism of Glycogen Phosphate as a Cause for Lafora Disease* , 2008, Journal of Biological Chemistry.

[11]  C. Worby,et al.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Scherer,et al.  Mutations in NHLRC1 cause progressive myoclonus epilepsy , 2003, Nature Genetics.

[13]  K. Yamakawa,et al.  Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. , 2002, Human molecular genetics.

[14]  K. Yamakawa,et al.  Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. , 2000, Human molecular genetics.

[15]  R. Michelucci,et al.  A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). , 1999, Human molecular genetics.

[16]  S. Scherer,et al.  Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy , 1998, Nature Genetics.

[17]  W. Matthews,et al.  Progressive myoclonus epilepsy without Lafora bodies. , 1969, Journal of neurology, neurosurgery, and psychiatry.

[18]  M. Ham,et al.  Progressive Myoclonus Epilepsy with Lafora Bodies. Clinical‐Pathological Features , 1963 .

[19]  H. D. de Jager,et al.  PROGRESSIVE MYOCLONUS EPILEPSY WITH LAFORA BODIES. CLINICAL-PATHOLOGICAL FEATURES. , 1963, Epilepsia.